Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02298712
Other study ID # BHUR 06-2018
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date August 20, 2018
Est. completion date February 28, 2021

Study information

Verified date February 2023
Source CENTOGENE GmbH Rostock
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Development of a new MS-based biomarker for the early and sensitive diagnosis of Hurler disease from plasma. Testing for clinical robustness, specificity and long-term stability of the biomarker.


Description:

Hurler disease - MPS I- (mucopolysaccharidosis I) is an inherited lysosomal storage disorder caused by a deficiency of alpha-L-iduronidase, a lysosomal enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs). If the enzyme is not present in sufficient quantities, the normal breakdown of GAGs is incomplete or blocked. The cell is then unable to excrete the carbohydrate residues and they accumulate in the lysosomes of the cell. This accumulation disrupts the cell's normal functioning and gives rise to the clinical manifestations of the disease. The incidence of MPS I is estimated to be at about 1 in 100,000 births. It is inherited in an autosomal recessive manner, affects males and females equally, and in most cases, both parents of an affected child are asymptomatic carriers of the disease. Types of MPS I. Children diagnosed with MPS I have historically been classified into one of three categories based on the severity of their symptoms and rate of disease progression. It has now become clear, however, that there is a wide spectrum of severity in MPS I with much overlap between the categories. • Hurler Syndrome: The most severe form of MPS I is characterized by progressive developmental delay and severe progressive physical problems. Death often occurs before 10 years of age. • Hurler-Scheie Syndrome: The intermediate form of MPS I is characterized by normal or near normal intelligence but more severe physical symptoms than those with Scheie Syndrome. • Scheie Syndrome: The attenuated form of MPS I is characterized by normal intelligence, usually normal height, and milder physical problems than Hurler-Scheie. These individuals potentially have a normal life span. Patients present within the first year of life with musculoskeletal alterations including short stature, dysostosis multiplex, thoracic-lumbar kyphosis, progressive coarsening of the facial features including large head with bulging frontal bones, depressed nasal bridge with broad nasal tip and anteverted nostrils, full cheeks and enlarged lips, cardiomyopathy and valvular abnormalities, neurosensorial hearing loss, enlarged tonsils and adenoids, and nasal secretion. Developmental delay is usually observed between 12 and 24 months of life and is primarily in the speech realm with progressive cognitive and sensorial deterioration. Hydrocephaly can occur after the age of two. Diffuse corneal compromise leading to corneal opacity becomes detectable from three years of age. Other manifestations include organomegaly, hernias and hirsutism. MPS1 syndrome is caused by mutations in the IDUA gene (4p16.3) leading to complete deficiency in the alpha-L-iduronidase enzyme and lysosomal accumulation of dermatan sulfate and heparan sulfate. Transmission is autosomal recessive. Early diagnosis is difficult because the first clinical signs are not specific, but it is very important to allow early treatment. Diagnosis is based on detection of increased urinary excretion of heparan and dermatan sulfate by 1, 9-dimethylmethylene blue (DMB) test and glycosaminoglycan (GAG) electrophoresis, and demonstration of enzymatic deficiency in leukocytes or fibroblasts. Genetic testing is available. Differential diagnoses include the milder form of mucopolysaccharidosis type 1, the MPS1-Scheie syndrome, although this form is associated with developmental delay with only slight cognitive impairment. New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood (plasma) of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity. Therefore it is the goal of the study to identify and validate a new biochemical marker from the plasma of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment. Though MPS1 disease is a pan-ethnic disorder, the prevalence of this autosomal-recessive disorder is elevated in countries with a higher frequency of consanguinity. Therefore, we estimate that every 400th newborn in Arabian countries may be eligible for inclusion due to high-grade suspicion of MPS1 disease, while approximately every 2000th newborn in a non-Arabian country may be eligible.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 28, 2021
Est. primary completion date February 28, 2021
Accepts healthy volunteers No
Gender All
Age group 2 Months and older
Eligibility INCLUSION CRITERIA - Informed consent will be obtained from the parents before any study related procedures. - Patients of both gender older than 2 month - The patient has a diagnosis of Hurler disease or a high-grade suspicion for Hurler disease - High-grade suspicion present, if one or more inclusion criteria are valid: 1. - Positive family anamnesis for Hurler disease 2. - Macrocephaly 3. - Deformed bones and stiff joints, especially the spine, hips, knees, wrists and fingers 4. - Musculoskeletal alterations including short stature 5. - Developmental delay and/or progressive mental deterioration EXCLUSION CRITERIA - No Informed consent from the parents before any study related procedures. - Patients of both gender younger than 2 month - No diagnosis of Hurler disease or no valid criteria for profound suspicion of Hurler disease

Study Design


Locations

Country Name City State
Egypt Children's Hospital, Faculty of Medicine, Ain Shams University Cairo
Germany Centogene AG Rostock
India Amrita Institute of Medical Sciences & Research Centre Cochin Kerala
India Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN) Mumbai
Sri Lanka Lady Ridgeway Hospital for Children Colombo 8

Sponsors (1)

Lead Sponsor Collaborator
CENTOGENE GmbH Rostock

Countries where clinical trial is conducted

Egypt,  Germany,  India,  Sri Lanka, 

Outcome

Type Measure Description Time frame Safety issue
Primary Development of a new MS-based biomarker for the early and sensitive diagnosis of Hurler disease from blood New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity. 24 months
Secondary Testing for clinical robustness, specificity and long-term stability of the biomarker the goal of the study to identify and validate a new biochemical marker from the blood of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment. 36 months
See also
  Status Clinical Trial Phase
Completed NCT00010361 - Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders N/A
Terminated NCT01963650 - Natural History Study of Children With Metachromatic Leukodystrophy
Withdrawn NCT03810690 - Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia Phase 1/Phase 2
Not yet recruiting NCT06337864 - Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria N/A
Completed NCT00477594 - Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Phase 2
Recruiting NCT04999566 - Cardiac Manifestation and Inherited Metabolic Diseases
Completed NCT02826694 - North Carolina Newborn Exome Sequencing for Universal Screening N/A
Completed NCT00607373 - Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Phase 3
Completed NCT00362180 - Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Phase 2
Active, not recruiting NCT02635269 - Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy N/A
Completed NCT00006061 - Study of Phosphatidylcholine in a Patient With Methionine Adenosyltransferase Deficiency N/A
Recruiting NCT04645498 - COVID-19 and Hereditary Metabolic Diseases
Completed NCT00099996 - Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia Phase 3
Completed NCT00006057 - Diagnostic and Screening Study of Genetic Disorders N/A
Completed NCT00694109 - An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia Phase 3
Completed NCT05123768 - Genetic Etiology in Patients With Cerebral Palsy